To assess the impact of HRG-ERBB2-ERBB3 and HRG-EGFR-ERBB3 signalling axis on cell viability and proliferation in EML4-ALK-harbouring NSCLC cells, we treated H3122 and H2228 cells with either ERL, SAP alone or in combination with LOR in the presence of HRG ligand (Fig. 5A, F). Here, ERBB2 is linked to non-small cell lung carcinoma.